Trials / Completed
CompletedNCT00212901
High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy
Addition of Angiotensin Receptor Blockade to ACE Inhibition Versus High Dose ACE Inhibition for Reduction of Proteinuria in Patients With Diabetic Nephropathy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Ottawa Hospital Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Investigation of wheather addition of angiotensin receptor blocker (Irbesartan) to recommended doses of angiotensin converting enzyme inhibitor (trandolapril) is more effective in decreasing amount of protein in urine in patients with diabetic kidney disease than high doses of trandolapril.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | High dose ACE-I vs ARB |
Timeline
- Start date
- 2004-08-01
- Completion
- 2006-09-01
- First posted
- 2005-09-21
- Last updated
- 2007-07-26
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00212901. Inclusion in this directory is not an endorsement.